09:23 AM EDT, 08/05/2025 (MT Newswires) -- Y-mAbs Therapeutics ( YMAB ) shares were up 104% in recent Tuesday premarket activity after it agreed to be acquired by SERB Pharmaceuticals for approximately $412 million.

Under the terms of the deal, SERB will issue an all-cash tender offer to buy all outstanding shares of Y-mAbs common stock, and Y-mAbs shareholders will receive $8.60 per share in cash.

The deal is slated to close by Q4, the company said.